Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

Date publication

novembre 2022

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr LAMBERT Aurélien

Tous les auteurs :
Dupont M, Carlier C, Gower-Rousseau C, Barbier-Lider P, Botsen D, Brasseur M, Burgevin A, Chourbagi C, D'Almeida R, Hautefeuille V, Hentzien M, Lambert A, Lamuraglia M, Lavau-Denes S, Lopez A, Parent D, Slimano F, Brugel M, Bouché O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36434607

Résumé

Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in the southeastern states of the USA. Tick's bites were suspected of generating cross-reactions between cetuximab and alpha-gal. This study aims was to describe the incidence and associated risk factors of CI-IRs, in the French areas chosen according to their Lyme disease incidence.

Mots clés

Alpha-gal, And neck neoplasms, Cetuximab, Head, Hypersensitivity, Infusion reaction, Lyme disease, Risk factors

Référence

BMC Cancer. 2022 11 25;22(1):1219